Search Results
488 results found for "Cost-efficient medications https://simplemedrx.top"
- Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most
- Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most
- Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most
- Anavex Life Sciences at The Michael J. Fox Foundation's Parkinson's Disease Therapeutics Conference
principle investigators, Veronica Francardo, PhD and Angela Cenci, MD, PhD, Professor of Experimental Medical Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media: Clayton
- Anavex Appoints Dr. Abraham Fisher to Scientific Advisory Board
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Reports Predicted Clinical Effect of Both ANAVEX 2-73 and ANAVEX PLUS
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free:
- Anavex to Announce Fiscal 2023 Third Quarter Financial Results on Tuesday August 8, 2023
Management will host a conference call on Tuesday August 8, 2023, at 8:30 am ET to review financial results (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease
About Alzheimer’s disease Alzheimer's disease is the most common cause of dementia, accounting for 60 (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most
- Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most
- Jefferies 2017 Global Healthcare Conference June 6-9
healthcare companies across the Biopharmaceuticals, Life Sciences, Healthcare Services, Healthcare IT and Medical
- Anavex Life Sciences Reports Dismissal of Appeal in the Cortina Lawsuit
Anavex Life Sciences Corp. et. al. lawsuit, without payment of any fees or costs by the Company. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most anavex.com Investors: Matthew Haines River East Investor Relations, LLC 917-733-9297 mhaines@rivereastir.com Media Dobson Media Group 203-258-0159 dennisdobsonjr@dobsonmediagroup.com
- Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most
